This analyst just upped his price target on Knight Therapeutics
Research Capital analyst Andre Uddin raised his target on Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:GUD) to C$9.80 from C$8.55, maintaining a “Buy” rating in a May 7 report after what he called another ...
19 hours ago